Breaks for Precision Medicine in Cancer: Development and Prospects of Spatiotemporal Transcriptomics.

IF 2.4 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Cancer Biotherapy and Radiopharmaceuticals Pub Date : 2024-02-01 Epub Date: 2024-01-05 DOI:10.1089/cbr.2023.0116

Shiqi Yan, Yilin Guo, Lizhong Lin, Wenling Zhang

{"title":"Breaks for Precision Medicine in Cancer: Development and Prospects of Spatiotemporal Transcriptomics.","authors":"Shiqi Yan, Yilin Guo, Lizhong Lin, Wenling Zhang","doi":"10.1089/cbr.2023.0116","DOIUrl":null,"url":null,"abstract":"<p><p>With the development of the social economy and the deepening understanding of cancer, cancer has become a significant cause of death, threatening human health. Although researchers have made rapid progress in cancer treatment strategies in recent years, the overall survival of cancer patients is still not optimistic. Therefore, it is essential to reveal the spatial pattern of gene expression, spatial heterogeneity of cell populations, microenvironment interactions, and other aspects of cancer. Spatiotemporal transcriptomics can help analyze the mechanism of cancer occurrence and development, greatly help precise cancer treatment, and improve clinical prognosis. Here, we review the integration strategies of single-cell RNA sequencing and spatial transcriptomics data, summarize the recent advances in spatiotemporal transcriptomics in cancer studies, and discuss the combined application of spatial multiomics, which provides new directions and strategies for the precise treatment and clinical prognosis of cancer.</p>","PeriodicalId":55277,"journal":{"name":"Cancer Biotherapy and Radiopharmaceuticals","volume":" ","pages":"35-45"},"PeriodicalIF":2.4000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biotherapy and Radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/cbr.2023.0116","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

With the development of the social economy and the deepening understanding of cancer, cancer has become a significant cause of death, threatening human health. Although researchers have made rapid progress in cancer treatment strategies in recent years, the overall survival of cancer patients is still not optimistic. Therefore, it is essential to reveal the spatial pattern of gene expression, spatial heterogeneity of cell populations, microenvironment interactions, and other aspects of cancer. Spatiotemporal transcriptomics can help analyze the mechanism of cancer occurrence and development, greatly help precise cancer treatment, and improve clinical prognosis. Here, we review the integration strategies of single-cell RNA sequencing and spatial transcriptomics data, summarize the recent advances in spatiotemporal transcriptomics in cancer studies, and discuss the combined application of spatial multiomics, which provides new directions and strategies for the precise treatment and clinical prognosis of cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

癌症精准医疗的突破口：时空转录组学的发展与前景。

随着社会经济的发展和人们对癌症认识的加深，癌症已成为威胁人类健康的重要死因。虽然近年来研究人员在癌症治疗策略上取得了突飞猛进的进展，但癌症患者的总体生存率仍不容乐观。因此，揭示癌症的基因表达空间模式、细胞群的空间异质性、微环境相互作用等方面的信息至关重要。时空转录组学有助于分析癌症发生和发展的机制，对癌症的精准治疗和临床预后的改善大有裨益。在此，我们回顾了单细胞RNA测序与空间转录组学数据的整合策略，总结了时空转录组学在癌症研究中的最新进展，并探讨了空间多组学的联合应用，为癌症的精准治疗和临床预后提供了新的方向和策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Biotherapy and Radiopharmaceuticals 医学-核医学

CiteScore

7.80

自引率

2.90%

发文量

审稿时长

3 months

期刊介绍： Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies. The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.